Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes

NCT01507311 · Completed

Last updated 2026-05-28

This clinical trial tested the effect of the medication liraglutide on insulin production in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 11 people

Who can join Ages 30–75 · all sexes

Timeline Started 1999-09 · est. completion 1999-12

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT01507311 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is to assess the effect of NNC 90-1170 (liraglutide) on pulsatile insulin secretion and insulin secretion after a standard meal in subjects with type 2 diabetes.

Treatments tested

liraglutide also known as NNC 90-1170 Drug

A single dose injected subcutaneously (under the skin)
placebo Drug

A single dose injected subcutaneously (under the skin)

Main thing measured	Insulin secretory burst mass
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01507311 ↗